Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer (Q34022546)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer |
scientific article |
Statements
1 reference
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer (English)
1 reference
David W Miles
1 reference
Arlene Chan
1 reference
Luc Y Dirix
1 reference
Xavier Pivot
1 reference
Piotr Tomczak
1 reference
Thierry Delozier
1 reference
Joo Hyuk Sohn
1 reference
Guenther G Steger
1 reference
Andreas Chlistalla
1 reference
Gilles Romieu
1 reference
24 May 2010
1 reference
1 reference
28
1 reference
20
1 reference
3239-3247
1 reference
Identifiers
1 reference
1 reference